Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats

In cirrhosis, splanchnic vasodilation contributes to portal hypertension, subsequent renal sodium retention, and formation of ascites. Urotensin II(U‐II) is a constrictor of large conductive vessels. Conversely, it relaxes mesenteric vessels, decreases glomerular filtration, and increases renal sodium retention. In patients with cirrhosis, U‐II plasma levels are increased. Thus, we investigated hemodynamic and renal effects of U‐II and its receptor antagonist, palosuran, in cirrhotic bile duct–ligated rats (BDL). In BDL and sham‐operated rats, we studied acute effects of U‐II (3 nmol/kg; intravenously) and palosuran (10 mg/kg; intravenously) and effects of oral administration of palosuran (30 mg/kg/day; 3 days) on hemodynamics and renal function. We localized U‐II and U‐II‐receptor (UTR) in livers and portal veins by immunostaining. We determined U‐II‐plasma levels by enzyme‐linked immunosorbent assay (ELISA), and mesenteric nitrite/nitrate‐levels by Griess‐reaction. RhoA/Rho‐kinase and endothelial nitric oxide synthase (eNOS) pathways were determined by western blot analysis and reverse transcription polymerase chain reaction (RT‐PCR) in mesenteric arteries. U‐II plasma levels, as well as U‐II and UTR‐receptor expression in livers and portal veins of cirrhotic rats were significantly increased. U‐II administration further augmented the increased portal pressure (PP) and decreased mean arterial pressure (MAP), whereas palosuran decreased PP without affecting MAP. The decrease in PP was associated with an increase in splanchnic vascular resistance. In mesenteric vessels, palosuran treatment up‐regulated expression of RhoA and Rho‐kinase, increased Rho‐kinase‐activity, and diminished nitric oxide (NO)/cyclic guanosine 3′,5′‐monophosphate (cGMP) signaling. Moreover, palosuran increased renal blood flow, sodium, and water excretion in BDL rats. Conclusion: In BDL rats, U‐II is a mediator of splanchnic vasodilation, portal hypertension and renal sodium retention. The U‐II‐receptor antagonist palosuran might represent a new therapeutic option in liver cirrhosis with portal hypertension. (HEPATOLOGY 2008.)

[1]  H. Krum,et al.  Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension , 2007, Liver international : official journal of the International Association for the Study of the Liver.

[2]  F. Nevens,et al.  Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho‐kinase and activation of endothelial nitric oxide synthase , 2007, Hepatology.

[3]  Roger Williams,et al.  Increased gene and protein expression of the novel eNOS regulatory protein NOSTRIN and a variant in alcoholic hepatitis. , 2007, Gastroenterology.

[4]  T. Sauerbruch,et al.  Vascular dysfunction in human and rat cirrhosis: Role of receptor‐desensitizing and calcium‐sensitizing proteins , 2007, Hepatology.

[5]  T. Sauerbruch,et al.  Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis , 2006, Gut.

[6]  S. Krähenbühl,et al.  Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients , 2006, Clinical pharmacology and therapeutics.

[7]  Yi-Zhun Zhu,et al.  The role of urotensin II in cardiovascular and renal physiology and diseases , 2006, British journal of pharmacology.

[8]  T. Katagiri,et al.  Human Urotensin II as a Link between Hypertension and Coronary Artery Disease , 2006, Hypertension Research.

[9]  Z. Ao,et al.  Urotensin II and renal function in the rat. , 2006, Kidney international.

[10]  K. Jakobs,et al.  Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. , 2006, Gastroenterology.

[11]  A. Davenport,et al.  Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation , 2006, British journal of pharmacology.

[12]  M. Clozel,et al.  The Urotensin-II Receptor Antagonist Palosuran Improves Pancreatic and Renal Function in Diabetic Rats , 2006, Journal of Pharmacology and Experimental Therapeutics.

[13]  J. Liao,et al.  Rho GTPases, statins, and nitric oxide. , 2005, Circulation research.

[14]  N. Ashton,et al.  Urotensin II: Ancient Hormone with New Functions in Vertebrate Body Fluid Regulation , 2005, Annals of the New York Academy of Sciences.

[15]  M. Clozel,et al.  Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System , 2004, Journal of Pharmacology and Experimental Therapeutics.

[16]  T. Sauerbruch,et al.  Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats , 2003, European journal of clinical investigation.

[17]  T. Yoshimoto,et al.  Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. , 2003, Endocrinology.

[18]  R. Busse,et al.  Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[19]  H. Schmidt,et al.  Phosphorylation of blood vessel vasodilator-stimulated phosphoprotein at serine 239 as a functional biochemical marker of endothelial nitric oxide/cyclic GMP signaling. , 2002, Molecular pharmacology.

[20]  T. Sauerbruch,et al.  Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. , 2001, Journal of hepatology.

[21]  W. Sessa,et al.  Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? , 2001, The Journal of pharmacology and experimental therapeutics.

[22]  J. Bertoglio,et al.  Human Urotensin II–Induced Contraction and Arterial Smooth Muscle Cell Proliferation Are Mediated by RhoA and Rho-Kinase , 2001, Circulation research.

[23]  J. Stasch,et al.  Effects of In Vivo Nitroglycerin Treatment on Activity and Expression of the Guanylyl Cyclase and cGMP-Dependent Protein Kinase and Their Downstream Target Vasodilator-Stimulated Phosphoprotein in Aorta , 2001, Circulation.

[24]  A. Davenport,et al.  Depressor and regionally‐selective vasodilator effects of human and rat urotensin II in conscious rats , 2001, British journal of pharmacology.

[25]  M. Van de Casteele,et al.  Characterisation of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow. , 2001, Pharmacology & therapeutics.

[26]  H. Sarau,et al.  Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey , 2000, British journal of pharmacology.

[27]  T. Meinertz,et al.  Vasodilator-Stimulated Phosphoprotein Serine 239 Phosphorylation as a Sensitive Monitor of Defective Nitric Oxide/cGMP Signaling and Endothelial Dysfunction , 2000, Circulation research.

[28]  S. Douglas,et al.  Human urotensin‐II is an endothelium‐dependent vasodilator in rat small arteries , 2000, British journal of pharmacology.

[29]  C. Chagneau,et al.  Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension. , 2000, Gastroenterology.

[30]  N. Aiyar,et al.  Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. , 2000, Journal of cardiovascular pharmacology.

[31]  J. Bosch,et al.  Complications of cirrhosis. I. Portal hypertension. , 2000, Journal of hepatology.

[32]  H. Sarau,et al.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.

[33]  M. Manns,et al.  Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. , 1999, The American journal of pathology.

[34]  K. Kaneda,et al.  Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. , 1999, Seminars in liver disease.

[35]  R. Groszmann,et al.  Nitric Oxide and Portal Hypertension: Its Role in the Regulation of Intrahepatic and Splanchnic Vascular Resistance , 1999, Seminars in liver disease.

[36]  U. Laufs,et al.  Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase* , 1998, The Journal of Biological Chemistry.

[37]  H. Saya,et al.  Association of the Myosin-binding Subunit of Myosin Phosphatase and Moesin: Dual Regulation of Moesin Phosphorylation by Rho-associated Kinase and Myosin Phosphatase , 1998, The Journal of cell biology.

[38]  Matthew W. Miller,et al.  Measurement of organ blood flow with coloured microspheres in the rat. , 1995, Cardiovascular research.

[39]  T. Porstmann,et al.  Enzyme immunoassay techniques. An overview. , 1992, Journal of immunological methods.

[40]  S. Avrameas.  Amplification systems in immunoenzymatic techniques. , 1992, Journal of immunological methods.

[41]  D. Häussinger,et al.  Hepatorenal reflex regulating kidney function , 1991, Hepatology.

[42]  S. Moncada,et al.  Hyperdynamic circulation in cirrhosis: a role for nitric oxide? , 1991, The Lancet.

[43]  D. Carter,et al.  Portal venous pressure and portasystemic shunting in experimental portal hypertension. , 1989, The American journal of physiology.

[44]  D. Longnecker,et al.  Anesthetic Influences on Regional Hemodynamics in Normal and Hemorrhaged Rats , 1984, Anesthesiology.

[45]  S. Tannenbaum,et al.  Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. , 1982, Analytical biochemistry.

[46]  S. Sherlock,et al.  Circulatory changes in chronic liver disease. , 1958, The American journal of medicine.